Enhertu Європейський Союз - хорватська - EMA (European Medicines Agency)

enhertu

daiichi sankyo europe gmbh - trastuzumab deruxtecan - neoplazme dojki - antineoplastična sredstva - breast cancerher2-positive breast cancerenhertu as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic her2-positive breast cancer who have received one or more prior anti-her2-based regimens. her2-low breast cancerenhertu as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic her2-low breast cancer who have received prior chemotherapy in the metastatic setting or developed disease recurrence during or within 6 months of completing adjuvant chemotherapy (see section 4. non-small cell lung cancer (nsclc)enhertu as monotherapy is indicated for the treatment of adult patients with advanced nsclc whose tumours have an activating her2 (erbb2) mutation and who require systemic therapy following platinum-based chemotherapy with or without immunotherapy. gastric cancerenhertu as monotherapy is indicated for the treatment of adult patients with advanced her2-positive gastric or gastroesophageal junction (gej) adenocarcinoma who have received a prior trastuzumab-based regimen.

Orladeyo Європейський Союз - хорватська - EMA (European Medicines Agency)

orladeyo

biocryst ireland limited - berotralstat dihydrochloride - angioedemas, nasljedni - other hematological agents - orladeyo is indicated for routine prevention of recurrent attacks of hereditary angioedema (hae) in adult and adolescent patients aged 12 years and older.

Jemperli Європейський Союз - хорватська - EMA (European Medicines Agency)

jemperli

glaxosmithkline (ireland) limited - dostarlimab - endometrial neoplasms - antineoplastic agents and antibody drug conjugates - jemparli is indicated as monotherapy for the treatment of adult patients with mismatch repair deficient (dmmr)/microsatellite instability-high (msi h) recurrent or advanced endometrial cancer (ec) that has progressed on or following prior treatment with a platinum-containing regimen.

PANCILLIN 200000 i.j./1 boca+ 600000 i.j./1 boca prašak za suspenziju za injekciju Боснія і Герцоговина - хорватська - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

pancillin 200000 i.j./1 boca+ 600000 i.j./1 boca prašak za suspenziju za injekciju

hemofarm proizvodnja farmaceutskih proizvoda d.o.o. banja luka - benzilpenicilinnatrijum, benzilpenicilinprokain - prašak za suspenziju za injekciju - 200000 i.j./1 boca+ 600000 i.j./1 boca - 1 bočica sa praškom za suspenziju za injekciju sadrži: 800 000 i.j. benzilpenicilina, što predstavlja smjesu od 200 000 i.j. benzilpenicilinnatrijuma + 600 000 i.j. benzilpenicilin, prokaina

Lutetium (177Lu) chloride Billev (previously Illuzyce) Європейський Союз - хорватська - EMA (European Medicines Agency)

lutetium (177lu) chloride billev (previously illuzyce)

billev pharma aps - lutetium (177lu) chloride - radionuklidno slikanje - terapeutski radiofarmaceutski pripravci - lutetium (177lu) chloride billev is a radiopharmaceutical precursor, and it is not intended for direct use in patients. it is to be used only for the radiolabelling of carrier molecules that have been specifically developed and authorised for radiolabelling with lutetium (177lu) chloride.

Locametz Європейський Союз - хорватська - EMA (European Medicines Agency)

locametz

novartis europharm limited  - gozetotide - radionuklidno slikanje - dijagnostički radiofarmaceutici - ovaj je lijek samo za dijagnostičku uporabu. locametz, after radiolabelling with gallium 68, is indicated for the detection of prostate specific membrane antigen (psma) positive lesions with positron emission tomography (pet) in adults with prostate cancer (pca) in the following clinical settings:primary staging of patients with high risk pca prior to primary curative therapy,suspected pca recurrence in patients with increasing levels of serum prostate specific antigen (psa) after primary curative therapy,identification of patients with psma positive progressive metastatic castration resistant prostate cancer (mcrpc) for whom psma targeted therapy is indicated (see section 4.

PANCILLIN 200 000i.j. + 600 000i.j. Prašak za suspenziju za injekciju Чорногорія - хорватська - CInMED-Institut za ljekove i medicinska sredstva Crne Gore

pancillin 200 000i.j. + 600 000i.j. prašak za suspenziju za injekciju

hemofarm a.d. vrŠac p.j. podgorica - benzilpenicilin, prokain benzilpenicilin - prašak za suspenziju za injekciju - 200 000i.j. + 600 000i.j.

PRALIP 40mg Tableta Чорногорія - хорватська - CInMED-Institut za ljekove i medicinska sredstva Crne Gore

pralip 40mg tableta

"glosarij" druŠtvo sa ograniČenom odgovornoŠĆu za trgovinu, grafiČku djelatnost, proizvodnju i usluge-cetinje - pravastatin - tableta - 40mg

PRALIP 20mg Tableta Чорногорія - хорватська - CInMED-Institut za ljekove i medicinska sredstva Crne Gore

pralip 20mg tableta

"glosarij" druŠtvo sa ograniČenom odgovornoŠĆu za trgovinu, grafiČku djelatnost, proizvodnju i usluge-cetinje - pravastatin - tableta - 20mg

ACLASTA 5mg/100ml Rastvor za infuziju Чорногорія - хорватська - CInMED-Institut za ljekove i medicinska sredstva Crne Gore

aclasta 5mg/100ml rastvor za infuziju

"novartis pharma services ag" dio stranog druŠtva podgorica - zoledronska kiselina - rastvor za infuziju - 5mg/100ml